- $1.53bn
- $1.53bn
- $2.07m
Brief: Cyclerion Updates On Timing Of Results Of Olinciguat Phase 2 Study In Sickle Cell Disease Patients
Brief: Cyclerion Therapeutics Says Entered Open Market Sale Agreement Of Up To $50 Million
Brief: Cyclerion Therapeutics Awarded Grant From Alzheimer's Association's Part Cloud-Gates Partnership Grant Program
Brief: Cyclerion Therapeutics Files For Shelf Of Up To 6.06 Mln Shares Of Common Stock By Selling Stockholders
Brief: Cyclerion Therapeutics Says Net Loss Was About $20 Million For Q2
Brief: Cyclerion Therapeutics Inc Files For Mixed Shelf Of Upto $150 Million - SEC Filing
Brief: Cyclerion Therapeutics Says Closed Enrollment For Olinciguat Phase 2 Strong Scd Study For Sickle Cell Disease Topline Data Readout Expected Q3 2020
Brief: Cyclerion Announces IW-6463 Phase 1 Healthy Volunteer Study Results That Support Further Development For Neurodegenerative Diseases
U.S. STOCKS ON THE MOVE-Boeing, PG&E, Wave Life Sciences, Wayfair
U.S. STOCKS ON THE MOVE-Boeing, IFF, PG&E, Mirum Pharma
U.S. STOCKS ON THE MOVE-Lyft, Apple, Tupperware, Crocs, General Electric
U.S. STOCKS ON THE MOVE-McKesson, Biogen, Cyclerion Therapeutics, Yum Brands, GrubHub
U.S. STOCKS ON THE MOVE-Yum Brands, Centene, Tupperware, Activision Blizzard
Brief: Cyclerion Therapeutics Inc Says On Oct. 29, Board Approved Reduction Of Company's Current Workforce By Approximately Thirty Full-Time Employees
Brief: Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results In Diabetic Nephropathy
U.S. STOCKS ON THE MOVE-J&J, GE, Mattel, Tupperware, Centene
Cyclerion Therapeutics: Set to touch all-time low on mid-stage trial failures
NASDAQ RESUMED
Brief: Cyclerion Therapeutics Announces Topline Phase 2 Results For sGC Stimulator Praliciguat In Heart Failure With Preserved Ejection Fraction